about
Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases.Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphomaBortezomib: A Review in Mantle Cell Lymphoma in Previously Untreated Patients Unsuitable for Stem-Cell Transplantation.Bortezomib in the treatment of mantle cell lymphoma.Mantle cell lymphoma: a model for risk-adapted treatment approach.
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Current and emerging therapies in mantle cell lymphoma.
@ast
Current and emerging therapies in mantle cell lymphoma.
@en
type
label
Current and emerging therapies in mantle cell lymphoma.
@ast
Current and emerging therapies in mantle cell lymphoma.
@en
prefLabel
Current and emerging therapies in mantle cell lymphoma.
@ast
Current and emerging therapies in mantle cell lymphoma.
@en
P2860
P1476
Current and emerging therapies in mantle cell lymphoma.
@en
P2093
L Kyle Brett
Michael E Williams
P2860
P2888
P304
P356
10.1007/S11864-013-0230-Z
P577
2013-06-01T00:00:00Z
P6179
1051211102